LCTX
Lineage Cell Therapeutics In
AMEX · Biotechnology
$1.70
+0.02 (+1.19%)
Open$1.70
Previous Close$1.68
Day High$1.74
Day Low$1.66
52W High$2.09
52W Low$0.37
Volume—
Avg Volume1.30M
Market Cap391.56M
P/E Ratio—
EPS$-0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+2,277.6% upside
Current
$1.70
$1.70
Target
$40.42
$40.42
$29.91
$40.42 avg
$53.83
Key Financials
| FY 2026 | FY 2025 | FY 2025 | |
|---|---|---|---|
| Revenue | 10.92M | 8.41M | 226.72M |
| Net Income | -21,420,460 | -14,847,823 | -56,382,666 |
| Profit Margin | -195.9% | -186.1% | -24.9% |
| EBITDA | -23,009,720 | -16,835,516 | -99,427,761 |
| Free Cash Flow | — | — | -46,193,350 |
| Rev Growth | +29.8% | +29.8% | +19.7% |
| Debt/Equity | 0.00 | 0.00 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |